PT  - JOURNAL ARTICLE
AU  - Thompson, Trevor
AU  - Whiter, Fiona
AU  - Gallop, Katy
AU  - Veronese, Nicola
AU  - Solmi, Marco
AU  - Newton, Paul
AU  - Stubbs, Brendon
TI  - NMDA receptor antagonists and pain relief
AID  - 10.1212/WNL.0000000000007238
DP  - 2019 Apr 02
TA  - Neurology
PG  - e1652--e1662
VI  - 92
IP  - 14
4099  - http://n.neurology.org/content/92/14/e1652.short
4100  - http://n.neurology.org/content/92/14/e1652.full
SO  - Neurology2019 Apr 02; 92
AB  - Objective We conducted a meta-analysis of controlled trials that used experimental models of acute pain and hyperalgesia to examine the analgesic effects of NMDA receptor (NMDAR) antagonists.Methods Six major databases were systematically searched (to March 2018) for studies using human evoked pain models to compare NMDAR antagonists with no-intervention controls. Pain outcome data were analyzed with random-effects meta-analysis.Results Searches identified 70 eligible trials (n = 1,069). Meta-analysis found that low-dose ketamine (<1 mg/kg) produced a decrease in hyperalgesic area (standardized mean difference 0.54, 95% confidence interval [CI] 0.34, 0.74, p < 0.001) and a 1.2-point decrease (95% CI 0.88, 1.44, p < 0.001) in pain ratings from 4.6 to 3.4 on a 0–10 scale (a 26% reduction). Similar analgesia was observed for acute and hyperalgesic models and was constant across the dosing range (0.03–1.00 mg/kg). Moderate to high variability in effect size was observed and mild side effects (e.g., sedation, sensory disturbance) were common. No effects of dextromethorphan were found.Conclusions Findings provide robust evidence for analgesic and antihyperalgesic effects of ketamine, supporting its utility for acute and chronic pain management. However, pain relief was modest, suggesting ketamine may potentially be most useful when opioids are contraindicated, rapid analgesia is required, or for pain resistant to conventional medication.CI=confidence interval; NMDAR=NMDA receptor; RVE=robust variance estimation; SMD=standardized mean difference